Future Policy for the Future of Precision Medicine

What regulations and policy tools are needed to bring tomorrow’s medical breakthroughs into today’s healthcare systems? That is the guiding question behind a new research initiative that puts governance and policy development – not technology itself – at the center. Focusing on precision medicine for inflammatory bowel disease (IBD), the project investigates how legal frameworks can enable the safe and effective use of cutting-edge technologies such as synthetic biology, multi-omics, and AI.

Through policy labs, testbeds, and an iterative process, the project develops new models for regulation and governance – always with real-world healthcare conditions and patient benefit in focus. The technological potential is vast: tailor-made biomolecules, genetically engineered cells, and predictive AI models may revolutionize how chronic diseases are treated. But innovation depends on regulatory readiness.

Led by RISE in collaboration with Region Skåne Innovation, Örebro University, and Pfizer AB, the project addresses legal and policy challenges that currently hinder progress. The outcome will provide concrete guidance for decision-makers and healthcare providers seeking to embrace innovation without compromising safety, integrity or quality of care.